Ovid Therapeutics Inc. recently released a corporate presentation highlighting its focus on developing medicines for conditions caused by neural hyperexcitability. The company is advancing a pipeline of highly specific small molecules with differentiated mechanisms of action. Key programs include the GABA-aminotransferase inhibitor OV329 for drug-resistant adult epilepsies and developmental epileptic encephalopathies, with Phase 1 topline results expected in Q3 2025 and Phase 2a initiation in Q1 2026. The KCC2 direct activator portfolio features OV350 IV, currently in Phase 1, and OV4071 oral, aimed at psychosis associated with Parkinson's disease and Lewy body dementia, with upcoming Phase 1 trials. Ovid holds a cash balance of $38.3 million, projected to fund operations into the early second half of 2026. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ovid Therapeutics Inc. published the original content used to generate this news brief on August 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.